The company has not filed an annual or quarterly report since its Q1 FY2018 10-Q, filed May 4, 2018. Its latest SEC filing is a SC 13G/A from Jun 11, 2018.
10-Q for Q1 FY2018, filed May 4, 2018
The sections below describe the company as of the FY2017 annual report.
Develops gene therapy treatments for patients with rare and life-threatening neurological genetic diseases, including spinal muscular atrophy, Rett syndrome and genetic ALS.
10-K for FY2017, filed Feb 28, 2018
No revenue was reported.
10-K for FY2017, filed Feb 28, 2018
10-Q for Q1 FY2018, filed May 4, 2018
−$222.1MView ↗
8-K, filed May 15, 2018
The aggregate consideration paid in the Offer and the Merger was approximately $8.7 billion, excluding related transaction fees and…View ↗
8-K, filed Apr 9, 2018
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, Parent will cause Merger Sub to…View ↗
Competes with Biogen, Voyager Therapeutics, Généthon, Ionis Pharmaceuticals, Roche Holding, Novartis, Trophos, Cytokinetics, Astellas, and Catalyst
10-K for FY2017, filed Feb 28, 2018At this time, there is one FDA‑approved, and one EMA‑approved, treatment for SMA. There are currently no treatments approved by the FDA for…View ↗
Loading...
